CROI 2016 Program at a Glance

Program and Agenda

571 Liver Transplantation in HIV/HBV-Coinfected Patients: A Cohort Study Christian Manzardo 1 ; Fernando Aguero 2 ; Miguel Montejo 3 ; Marino Blanes 4 ; Manuel Abradelo 5 ; Santos del Campo 6 ; Lluis Castells 7 ; Antoni Rafecas 8 ; Antoni Rimola 1 ; José M. Miro 9 ; for the Spanish Liver Transplantation in HIV-Infected PatientsWorking Group. 1 HospClinic-IDIBAPS-UnivofBarcelona,Barcelona,Spain; 2 HospClínic deBarcelona,Barcelona,Spain; 3 HospUniversitarioCruces,Barakaldo, Spain; 4 HospUniversitariLaFe,Valencia,Spain; 5 HospUniversitario12 deOctubre,Madrid,Spain; 6 HospRamonyCajal,Madrid,Spain; 7 Hosp UniversitarioValld Hebron,Barcelona,Spain; 8 HospdeBellvitge-IDIBELL, UnivofBarcelona,L’HospitaletdeLlobregat,Spain; 9 HospClinic-IDIBAPS, UnivdeBarcelona,Barcelona,Spain 2:45 PM-4:00 PM HCV Infection: Therapeutic Studies and Drug Resistance 572 Incidence and Risk Factors of Acute Rejection in HIV+ Liver Transplant Recipients Session P-N6 Poster Abstracts Hall A/B Christian Manzardo 1 ; Fernando Aguero 2 ; Antoni Rafecas 3 ; Jesús Fortún 4 ; Marino Blanes 5 ; Magdalena Salcedo 6 ; Itxarone Bilbao 7 ; Asunción Moreno 1 ; Antoni Rimola 1 ; José M. Miro 8 ; for the Spanish Foundation for AIDS Research and Prevention, LiverTransplantation Investigators 1 HospClinic-IDIBAPS-UnivofBarcelona,Barcelona,Spain; 2 HospClínic deBarcelona,Barcelona,Spain; 3 HospdeBellvitge-IDIBELL,Univof Barcelona,L’HospitaletdeLlobregat,Spain; 4 HospRamonyCajal, Madrid,Spain; 5 HospUniversitariLaFe,Valencia,Spain; 6 HospGeneral UniversitarioGregorioMarañón,Madrid,Spain; 7 HospUniversitarioVall d Hebron,Barcelona,Spain; 8 HospClinic-IDIBAPS,UnivdeBarcelona, Barcelona,Spain 573 Retreatment of HCV/HIV-Coinfected Patients Who Failed 12Weeks of LDV/SOF Curtis L. Cooper 1 ; Susanna Naggie 2 ; Michael S. Saag 3 ; Jenny C. Yang 4 ; Luisa M. Stamm 4 ; Hadas Dvory-Sobol 4 ; Philip S. Pang 4 ; John G. McHutchison 4 ; Douglas Dieterich 5 ; Mark Sulkowski 6 1 OttawaHosp-UnivofOttawa,Ottawa,ON,Canada; 2 DukeUnivSchof Med,Durham,NC,USA; 3 UnivofAlabamaatBirmingham,Birmingham, AL,USA; 4 GileadScis, Inc,FosterCity,CA,USA; 5 MountSinaiHosp,New York,NY,USA; 6 JohnsHopkinsUniv,Baltimore,MD,USA 574 TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/ r+Dasabuvir+RBV for HCV/HIV Coinfection 1 UnivofCaliforniaSanDiego,SanDiego,CA,USA; 2 UnivofAlabamaat Birmingham,Birmingham,AL,USA; 3 AbbVie Inc,NorthChicago, IL,USA; 4 QuestClinicalRsr,SanFrancisco,CA,USA; 5 RuthM.RothsteinCORECntr, Chicago, IL,USA; 6 AIDSHlthcareFndn,BeverlyHills,CA,USA; 7 Peter J RuaneMD, Inc,LosAngeles,CA,USA 575 NS5A and NS5B Minor Variant Analyses in HCV/HIV Patients Failing Treatment With DCV/SOF Dennis Hernandez 1 ; Saumya Pant 2 ; Nannan Zhou 1 ; Fiona McPhee 1 1 Bristol-MyersSquibb,Wallingford,CT,USA; 2 Bristol-MyersSquibb, Princeton,NJ,USA David L.Wyles 1 ; Michael S. Saag 2 ; RogerTrinh 3 ; Jacob Lalezari 4 ; Oluwatoyin Adeyemi 5 ; Laveeza Bhatti 6 ; Amit Khatri 3 ;Yiran B. Hu 3 ; Nancy S. Shulman 3 ; Peter Ruane 7

576 Safety and Tolerability of Elbasvir/Grazoprevir in Chronic Hepatitis C Infection Mark S. Sulkowski 1 ; Geoffrey M. Dusheiko 2 ; Michael Manns 3 ; John M.Vierling 4 ; Rajender Reddy 5 ; Paul Kwo 6 ; Eric Lawitz 7 ; JaniceWahl 8 ; Barbara Haber 8 1 JohnsHopkinsUniv,Baltimore,MD,USA; 2 RoyalFreeHospUnivColl London,London,UK; 3 MedizinischeHochschuleHannover,Hannover, Germany; 4 BaylorCollofMed,Houston,TX,USA; 5 Hospof theUniv ofPennsylvania,Philadelphia,PA,USA; 6 IndianaUnivSchofMed, Indianapolis, IN,USA; 7 TexasLiver Inst,SanAntonio,TX,USA; 8 Merck& Co, Inc,Kenilworth,NJ,USA 577 HCV Resistance to Daclatasvir/Sofosbuvir Across Different Genotypes in the Real Life Slim Fourati 1 ; Christophe Hezode 1 ; Alexandre Soulier 1 ; Lila Poiteau 1 ; Marion Lavert 1 ; Christophe Rodriguez 2 ; Stephane Chevaliez 1 ; Jean- Michel Pawlotsky 1 1 INSERMU955,Créteil,France; 2 InstMondordeRechercheBiomédicale INSERMU955,Créteil,France 578 Polymorphisms at Codon 28 of HCV NS5A Impact NS5A Inhibitor Susceptibility Alicia Newton ; Arne Frantzell; Christos Petropoulos;Wei Huang MonogramBioScis,SouthSanFrancisco,CA,USA 579 Genotypic and Phenotypic Characterization of Clinical HCV NS5A Drug Resistance Wei Huang ; Alicia Newton; Arne Frantzell; Jennifer Cook; Dongmei Yang; Joseph M.Volpe; Charles M.Walworth; Jeannette M.Whitcomb; Jacqueline D. Reeves; Christos Petropoulos MonogramBioScis,SouthSanFrancisco,CA,USA 580 Resistance Associated Variants: Data From the NIAID SYNERGY Trial Eleanor M.Wilson 1 ; Sarah Kattakuzhy 2 ; Hongmei Mo 3 ; Anuoluwapo Osinusi 3 ; Henry Masur 4 ; Anita Kohli 5 ; Shyam Kottilil 6

Poster Listings

1 InstofHumanVirology,Baltimore,MD,USA; 2 InstofHumanVirology, Bethesda,MD,USA; 3 GileadScis, Inc,FosterCity,CA,USA; 4 NIH,Bethesda, MD,USA; 5 DignityHlth,St. Joseph’sHosp,Phoenix,AZ,USA; 6 Univof MarylandMedCntr,Baltimore,MD,USA

Session P-N7 Poster Abstracts

Hall A/B

2:45 PM-4:00 PM HCV Therapeutics: Observational Experiences and “Real-World”Studies 581 Efficacy and Safety of Sofosbuvir-Based Regimens in Clinical Practice Adeel A. Butt 1 ; PengYan 2 ; Obaid Shaikh 3 ; RaymondT. Chung 4 ; Kenneth E. Sherman 5 ; for the ERCHIVES Study Group 1 HamadHlthcareQuality Inst,Doha,Qatar; 2 VAPittsburghHlthcare System,Pittsburgh,PA,USA; 3 UnivofPittsburgh,Pittsburgh,PA,USA; 4 HarvardMedSch,Boston,MA,USA; 5 UnivofCincinnati,Cincinnati, OH,USA

89

CROI 2016